The promise of genomics and proteomics in immunotoxicology and immunopharmacology

Immunotoxicology and Immunopharmacology, Third Edition

Volumn , Issue , 2006, Pages 79-96

  Pruett, Stephen B ^a   Holladay, Steven D ^b   Renee Prater, M ^c   Yucesoy, Berran ^d   Luster, Michael I ^d  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^c EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957927028     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (89)

1. Luster, M. I., et al., Risk Assessment in Immunotoxicology. I. Sensitivity and predictability of immune tests, Fundam. Appl. Toxicol., 18, 200, 1992.
2. Luster, M. I., et al., Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests, Fundam. Appl. Toxicol. 21, 71, 1993.
3. Germolec, D. R., et al., The accuracy of extended histopathology to detect immunotoxic chemicals, Toxicol. Sci., 82, 504, 2004.
4. Ideker, T., Galitski, T., and Hood, L., A new approach to decoding life: systems biology, Ann. Rev. Genomics Hum. Genet., 2, 343, 2001.
5. Hayes, K. R., et al., EDGE: a centralized resource for the comparison, analysis, and distribution of toxicogenomic information, Mol. Pharmacol., 67, 1360, 2005.
6. Kier, L. D., et al., Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro, Mutat. Res., 549, 101, 2004.
7. Waring, J. F., et al., Development of a DNA microarray for toxicology based on hepatotoxin- regulated sequences, EHP Toxicogenomics, 111, 53, 2003.
8. Hamadeh, H. K., et al., Gene expression analysis reveals chemical-specific profiles, Toxicol. Sci., 67, 219, 2002.
9. Merrick, B. A. and Bruno, M. E., Genomic and proteomic profiling for biomarkers and signature profiles of toxicity, Curr. Opin. Mol. Ther., 6, 600, 2004.
10. Dudoit, S., Gentleman, R. C., and Quackenbush, J., Open source software for the analysis of microarray data, Biotechniques, Suppl., 45, 2003.
11. Yuen, T., et al., Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays, Nucleic Acids Res., 30, e48, 2002
12. Naef, F., Socci, N. D., and Magnasco, M., A study of accuracy and precision in oligonucleotide arrays: extracting more signal at large concentrations, Bioinformatics, 19, 178, 2003.
13. Pruett, S. B., et al., Suppression of Innate Immunity by Ethanol: A Global Perspective and a New Mechanism Beginning with Inhibition of Signaling Through Toll-Like Receptor 3, J. Immunol., 173, 2715, 2004.
14. Jolly, R. A., et al., Pooling Samples Within Microarray Studies: A Comparative Analysis of Rat Liver Transcription Response to Prototypical Toxicants, Physiol. Genomics, 22, 346, 2005.
15. Palmer, L. J. and Cookson, W. O., Using single nucleotide polymorphisms as a means to understanding the pathophysiology of asthma, Respir. Res., 2, 102, 2001.
16. Silverman, E. K. and Palmer, L. J., Case-control association studies for the genetics of complex respiratory diseases, Am. J. Respir. Cell. Mol. Biol., 22, 645, 2000.
17. Risch, N. J., Searching for genetic determinants in the new millennium, Nature, 405, 847, 2000.
18. Rogers, P. D., et al., Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis, J. Antimicrob. Chemother., 50, 811, 2002.
19. Galon, J., et al., Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells, FASEB J., 16, 61, 2002.
20. Spinozzi, F., et al., Biological effects of montelukast, a cysteinyl-leukotriene receptorantagonist, on T lymphocytes, Clin. Exp. Allergy, 34, 1876, 2004.
21. Jin, J. Y., et al., Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays, J. Pharmacol. Exp. Ther., 307, 93, 2003.
22. Ramakrishnan, R., et al., Pharmacodynamics and pharmacogenomics of methylprednisolone during 7- day infusions in rats, J. Pharmacol. Exp. Ther., 300, 245, 2002.
23. Korcheva, V., et al., Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome, Am. J. Pathol., 166, 323, 2005.
24. Ezendam, J., et al., Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats, Environ. Health. Perspect., 112, 782, 2004.
25. McDowell, S. A., et al., The role of the receptor tyrosine kinase Ron in nickel-induced acute lung injury, Am. J. Respir. Cell. Mol. Biol., 26, 99, 2002.
26. Spagnuolo, P. J. and MacGregor, R. R., Acute ethanol effect on chemotaxis and other components of host defense, J. Lab. Clin. Med., 86, 24, 1975.
27. Mandrekar, P., Catalano, D., Girouard, L., et al., Human monocyte IL-10 production is increased by acute ethanol treatment, Cytokine 8, 567, 1996.
28. Boe, D. M., Nelson, S., Zhang, P., et al., Acute ethanol intoxication suppresses lung chemokine production following infection with Streptococcus pneumoniae, J. Infect. Dis., 184, 1134, 2001.
29. Goral, J. and Kovacs, E. J., In vivo ethanol exposure down-regulates TLR2-, TLR4-, and TLR9-mediated macrophage inflammatory response by limiting p38 and ERK1/2 activation, J. Immunol. 174, 456, 2005.
30. Fisher, M. T., Nagarkatti, M., and Nagarkatti, P. S., Combined screening of thymocytes using apoptosis-specific cDNA array and promoter analysis yields novel gene targets mediating TCDD-induced toxicity, Toxicol. Sci., 78, 116, 2004.
31. McKallip, R. J., Nagarkatti, M., and Nagarkatti, P. S., Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response, J. Immunol., 174, 3281, 2005.
32. Boverhof, D.R., et al., 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces suppressor of cytokine signaling 2 in murine B cells, Mol. Pharmacol., 66, 1662, 2004.
33. Ingelman-Sundberg, M., Oscarson, M., and McLellan, R. A., Polymorphic human cyto- chrome P450 enzymes: an opportunity for individualized drug treatment, Trends Pharmacol. Sci., 20, 342, 1999.
34. Vidigal, P. G., Germer, J. J., and Zein, N. N., Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin, J. Hepatol., 36, 271, 2002.
35. Libura, J., et al., Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene, Eur. Respir. J., 19, 912, 2002.
36. Pirmohamed, M., et al., TNFalpha promoter region gene polymorphisms in carbamazepinehypersensitive patients, Neurology, 56, 890, 2001.
37. Hetherington, S., et al., Genetic variations in HLA-B region and hypersensitivity reactions to abacavir, Lancet, 359, 1121, 2002.
38. Mallal, S., et al., Association between presence of HLA-B*5701, HLA-DR7, and HLADQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet, 359, 727, 2002.
39. Kang, C. P., et al., The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis, Rheumatology (Oxford), 44, 547, 2005.
40. Green, S. A., et al., The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s), Eur. J. Pharmacol., 421, 141, 2001.
41. Pandya, U., et al., Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil, Biochem. Biophys. Res. Commun., 278, 258, 2000.
42. Sookoian, S., et al., A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension, Am. J. Gastroenterol., 100, 636, 2005.
43. Yucesoy, B., et al., Association of tumor necrosis factor-alpha and interleukin-1 gene polymorphisms with silicosis, Toxicol. Appl. Pharmacol., 172, 75, 2001.
44. McCanlies, E. C., et al., The association between HLA-DPB1(Glu69) and chronic beryllium disease and beryllium sensitization, Am. J. Ind. Med., 46, 95, 2004.
45. Sleijffers, A., et al., Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination, J. Immunol., 170, 3423, 2003.
46. Yucesoy, B., et al., IL-1beta gene polymorphisms influence hepatitis B vaccination, Vaccine, 20, 3193, 2002.
47. Luhe, A., et al., Toxicogenomics in the pharmaceutical industry: Hollow promises or real benefit? Mutat. Res., 575, 102, 2005.
48. Wilkins, M., et al., in Proteome Research: New Frontiers in Functional Genomics (Principles and Practice) Springer, New York, 1997, pp. 211.
49. Naistat, D. M. and Leblanc, R., Proteomics, J. Environ. Pathol. Toxicol. Oncol., 23, 161, 2004.
50. Graves, P. R. and Haystead, T. A., A functional proteomics approach to signal transduction, Recent. Prog. Horm. Res., 58, 2003
51. Fountoulakis, M., Two-dimensional electrophoresis, in Encyclopedia of separation science II/Eletrophoresis Academic Press, London, 2000, pp. 1356-1363.
52. Clynen, E., De Loof, A., and Schoofs, L., The use of peptidomics in endocrine research, Gen. Comp. Endocrinol., 132, 1, 2003.
53. Suckau, D., et al., A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics, Anal. Bioanal. Chem., 376, 952, 2003.
54. McGuire, J. F. and Casado, B., Proteomics: a primer for otologists, Otol. Neurotol., 25, 842, 2004.
55. de Hoog, C. L. and Mann, M., Proteomics, Ann. Rev. Genomics Hum. Genet., 5, 267, 2004.
56. Rosengren, A. T., et al., Proteomic and transcriptomic characterization of interferon-alphainduced human primary T helper cells, Proteomics, 5, 371, 2005.
57. Caprioli, R. M., Farmer, T. B., and Gile, J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS, Anal. Chem., 69 (23), 4751-60, 1997.
58. Meri, S. and Baumann, M., Proteomics: posttranslational modifications, immune responses and current analytical tools, Biomol. Eng., 18, 213, 2001.
59. Patton, W. F., Detection technologies in proteome analysis, J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 771, 3, 2002.
60. Turecek, F., Mass spectrometry in coupling with affinity capture-release and isotope-coded affinity tags for quantitative protein analysis, J. Mass Spectrom., 37, 1, 2002.
61. Gygi, S. P., et al., Quantitative analysis of complex protein mixtures using isotope-coded affinity tags, Nat. Biotechnol., 17, 994, 1999.
62. Moseley, M. A., Current trends in differential expression proteomics: isotopically coded tags, Trends Biotechnol., 19 (10 Suppl), S10, 2001.
63. LoPachin, R. M., et al., Application of proteomics to the study of molecular mechanisms in neurotoxicology, Neurotoxicology, 24, 761, 2003.
64. Barrier, M. and Mirkes, P. E., Proteomics in developmental toxicology, Reprod. Toxicol., 19, 291, 2005.
65. Mullick, A., et al., Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain, Infect. Immun., 72, 5868, 2004.
66. Xu, Y., et al., HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy, Proc. Natl. Acad. Sci. U S A, 101, 7070, 2004.
67. Zhou, Q., et al., Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein, Infect. Immun., 73, 935, 2005.
68. Huang, L., et al., Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes, Arterioscler. Thromb. Vasc. Biol., 24, 1783, 2004.
69. Laurence, A., et al., Identification of pro-interleukin 16 as a novel target of MAP kinases in activated T lymphocytes, Eur. J. Immunol., 34, 587, 2004.
70. Wilkins, M. R., What do we want from proteomics in the detection and avoidance of adverse drug reactions, Toxicol. Lett., 127, 245, 2002.
71. Ultrecht, J., Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr. Drug Metab., 1, 133, 2000.
72. Anderson, N. L., et al., Simultaneous measurement of hundreds of liver proteins: application in assessment of liver function, Toxicol. Pathol., 24, 72, 1996.
73. Myers, T. G., et al., A protein expression database for the molecular pharmacology of cancer, Electrophoresis, 18, 647, 1997.
74. Weinstein, J. N., et al., An information-intensive approach to the molecular pharmacology of cancer, Science, 275, 343, 1997.
75. Gygi, S. P., Rist, B., and Aebersold, R., Measuring gene expression by quantitative proteome analysis, Curr. Opin. Biotechnol., 11, 396, 2000.
76. Godovac-Zimmermann, J. and Brown, L. R., Perspectives for mass spectrometry and functional proteomics, Mass Spectrom. Rev., 20, 1, 2001.
77. Peng, J. and Gygi, S. P., Proteomics: the move to mixtures, J. Mass Spectrom., 36, 1083, 2001.
78. Moffatt, M. F. and Cookson, W. O., Tumour necrosis factor haplotypes and asthma, Hum. Mol. Genet., 6, 551, 1997.
79. Mapp, C. E., et al., Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates, J. Allergy Clin. Immunol., 109, 867, 2002.
80. Yee, L. J., et al., Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection, Genes Immun., 1, 386, 2000.
81. Takamatsu, M., et al., Genetic polymorphisms of interleukin-1beta in association with the development of alcoholic liver disease in Japanese patients, Am. J. Gastroenterol., 95 (5), 1305, 2000.
82. Ma, Q., et al., GSTP1 A1578G (Ile105Val) polymorphism in benzidine-exposed workers: an association with cytological grading of exfoliated urothelial cells, Pharmacogenetics, 13, 409, 2003.
83. Rebeck, G. W., Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer’s disease, Neurosci. Lett., 293, 75, 2000.
84. Boin, F., et al., Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia, Mol. Psychiat., 6, 79, 2001.
85. Maier, L. A., et al., High beryllium-stimulated TNF-alpha is associated with the -308 TNFalpha promoter polymorphism and with clinical severity in chronic beryllium disease, Am. J. Respir. Crit. Care Med., 164, 1192, 2001.
86. Sakao, S., et al., Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med., 163, 420, 2001.
87. Wu, L., et al., Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease, Thorax, 59, 126, 2004.
88. Zhai, R., et al., Polymorphisms in the promoter of the tumor necrosis factor-alpha gene in coal miners, Am. J. Ind. Med., 34, 318, 1998.
89. Yucesoy, B., et al., Polymorphisms of the IL-1 gene complex in coal miners with silicosis, Am. J. Ind. Med., 39, 286, 2001.